First Australian medicinal cannabis produced in Queensland

THC Global Group (ASX:THC) has completed the first farm-to-pharma processing of medicinal cannabis in Australia at its Southport manufacturing facility (pictured) in Queensland. The Southport Facility is the largest pharmaceutical bio-floral extraction facility in the Southern Hemisphere and is licenced and permitted to process medicinal cannabis. THC Global CEO Ken Charteris said: “Completing this Australian…

Major project status for medicinal cannabis

The federal government has granted major project status for the development of new medicinal cannabis facilities in South East Queensland and regional Victoria. Major project status has been granted to Hydroganics for a multi-stage $333 million medicinal cannabis facility in Queensland and Canopy Growth for a $70 million facility in Victoria. Hydroganics is expected to…

Althea to expand into medicinal cannabis manufacturing

Medicinal cannabis cultivator and manufacturer Althea Global (ASX: AGH) has ended the year hitting milestones with 3,031 patients prescribed the drug by 375 healthcare professionals. Only 159 patients had been prescribed the company’s products a year ago. CEO Josh Fegan told the annual general meeting that the company also entered the United Kingdom market and…

Baxter Labs celebrates 25 years production

Melbourne pharmaceutical manufacturer Baxter Laboratories has celebrated 25 years as a manufacturer of skin care products, sunscreens and topical pharmaceutical. Staff paused to celebrate 25 years of service at the plant yesterday (below). The company offers a complete service to third parties from research and development to regulatory services, manufacturing, filling , warehousing and global…

IDT Australia looks to improve on flat results

Pharmaceutical manufacturer and clinical trials group IDT Australia (ASX: IDT) is confident of better times ahead following a flat 2019 which saw revenue down on the previous year. The company, which manufactures pharmaceutical active ingredient and consumer dosage products, as well as conducting clinical trials, has recovered from an adverse situation with the US FDA…

Bionomics receives huge R&D tax refund

Biopharmaceutical developer Bionomics (ASX: BNO) has received a $5.2 million R&D Tax Incentive Refund for 2018/2019 recognising its intense product development efforts. The company, which is developing a number of novel drug candidates based its unique ionX platform technology, appears to have received one of the largest refunds for the year. While most young drug…

THC Global set to manufacture medicinal cannabis in Queensland

Medicinal cannabis producer THC Global (ASX: THC) is to begin production at its Southport manufacturing facility following the issue of permits from Australia’s Office of Drug Control (ODC). CEO Ken Charteris revealed in a statement this morning the issue of permits covering production from licensed and permitted medicinal cannabis growers, including from the Company’s own…

Noxopharm reports anti-cancer effects of Veyonda

Sydney anti-cancer treatment company Noxopharm (ASX: NOX) has reported anti-cancer effects of its Veyonda treatment in a small group of patients suffering advanced prostate cancer. The 14 patients’ cancers were metastatic and they had exhausted all treatment options when given Veyonda in association with low-dosage radiation in a single lesion. After six months, cancer progression…

The future of nanotechnology in medicine – infographic

Around the world, researchers are increasingly thinking smaller to solve some of the biggest problems in medicine. Though most biological processes happen at the nano level, it wasn’t until recently that new technological advancements helped in opening up the possibility of nanomedicine to healthcare researchers and professionals. Today’s infographic, which comes to us from Best…